| abstract |
The invention relates to the technical field of biomedicine, in particular to the application of defensin DLP4 in the treatment of piglet exudative dermatitis. In the present invention, it is found that the defensin DLP4 has high-efficiency in vitro bactericidal activity against multi-drug resistant Staphylococcus suis, and has the characteristics of rapid, high-efficiency, and non-rebound bactericidal. For exudative dermatitis in piglets infected with Staphylococcus suis, the defensin DLP4 can significantly relieve the symptoms of dermatitis, promote skin recovery, regulate inflammatory factors, reduce the amount of bacteria in the organs, and protect the organs from organic damage. Purpose of treatment of exudative dermatitis. |